Epiregulin as a therapeutic target in non-small-cell lung cancer

Código QR

Epiregulin as a therapeutic target in non-small-cell lung cancer

Noriaki Sunaga,1,2 Kyoichi Kaira2,31Oncology Center, Gunma University Hospital, 2Department of Medicine and Molecular Science, 3Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Gunma, JapanAbstract: Epiregulin (EREG) belongs to the ErbB family of ligands. ER...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sunaga N, Kaira K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/584722e9cd264212b8c822f59bb017e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012)

Afatinib treatment in advanced non-small cell lung cancer
por: Hurwitz JL, et al.
Publicado: (2011)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou N, et al.
Publicado: (2014)

Emerging treatment options in the management of non-small cell lung cancer
por: Filosso PL, et al.
Publicado: (2011)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami S, et al.
Publicado: (2015)

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
por: Stasi I, et al.
Publicado: (2014)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns MW, et al.
Publicado: (2015)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise AM, et al.
Publicado: (2014)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
por: Gou LY, Wu YL
Publicado: (2014)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
por: Barbara Melosky, et al.
Publicado: (2021)

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study
por: Minami S, et al.
Publicado: (2015)

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
por: Berghmans T, et al.
Publicado: (2012)

Non-small-cell lung carcinoma: role of the Notch signaling pathway
por: Barse L, et al.
Publicado: (2015)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild SI
Publicado: (2014)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
por: Yawen Zheng, et al.
Publicado: (2021)

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
por: Takeda M, et al.
Publicado: (2011)

Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer
por: Karam SD, et al.
Publicado: (2013)

Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis
por: Ke Gong MBBS, et al.
Publicado: (2021)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Marianne Oulhen, et al.
Publicado: (2021)

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
por: Ke Cheng, et al.
Publicado: (2021)

Correction: Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
Publicado: (2021)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer
por: Zienolddiny S, et al.
Publicado: (2011)

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
por: Gabriela Palma, et al.
Publicado: (2021)

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
por: Wallace Akerley, et al.
Publicado: (2021)

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
por: Fengtan Li, et al.
Publicado: (2021)

A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
por: Yokoi T, et al.
Publicado: (2012)

Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients
por: Justyna Durślewicz MSc, et al.
Publicado: (2021)

Aberrant Alteration of Circulating Lymphocyte Subsets in Small Cell Lung Cancer Patients Treated with Radiotherapy
por: Hui Li MD, et al.
Publicado: (2021)

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
por: Fragoulakis VF, et al.
Publicado: (2012)

MET targeted therapy for lung cancer: clinical development and future directions
por: Feng Y, et al.
Publicado: (2012)

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
por: Mark A. Socinski, et al.
Publicado: (2021)

NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis
por: Lu Peng, et al.
Publicado: (2021)

Emerging role of G9a in cancer stemness and promises as a therapeutic target
por: Joshua R. Haebe, et al.
Publicado: (2021)

Emerging treatments in lung cancer – targeting the RLIP76 molecular transporter
por: Goldfinger LE, et al.
Publicado: (2013)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao M, et al.
Publicado: (2015)

Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy
por: Yu BF, et al.
Publicado: (2015)

Adjuvant targeted therapy for non-small cell lung cancer
por: Konstantin K. Laktionov, et al.
Publicado: (2020)

Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
por: Adrián Sánchez-Fdez, et al.
Publicado: (2021)